title: [Postoperative intravesical instillation of THP for superficial bladder tumor: clinical results of prophylactic effects on the recurrence. Fukushima THP Research Group].
abstract: Intravesical instillation of pirarubicin (THP) was performed on 66 patients with superficial bladder cancer after transurethral resection to evaluate the prophylactic effect against tumor recurrence. Intravesical chemotherapy was carried out at the concentration of 20mg/40ml. THP was initially instilled three times for one week, following instillation of every two weeks for ten times, and then every one month for seven times. Bladder irritability was demonstrated 21 of 66 cases (31.8%). Although there was a case of contracted bladder, generalized side effect was no case. Eligible cases for evaluation of efficacy were 43 out of 66 patients. The non-recurrence rate (by Kaplan-Meier's method) at one and two years were 90.4% and 77.8%, respectively. Intravesical THP instillation seems to be effective for the purpose of prophylaxis against the recurrence of superficial bladder tumor.
authors.affiliation: Dept. of Urology, Fukushima Medical College.
authors.forename: K
authors.initials: K
authors.lastname: Aikawa
authors.forename: C
authors.initials: C
authors.lastname: Irisawa
authors.forename: O
authors.initials: O
authors.lastname: Muraki
authors.forename: O
authors.initials: O
authors.lastname: Yamaguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Shiraiwa
authors.forename: M
authors.initials: M
authors.lastname: Noguchi
authors.forename: M
authors.initials: M
authors.lastname: Koguchi
authors.forename: J
authors.initials: J
authors.lastname: Yokoyama
authors.forename: K
authors.initials: K
authors.lastname: Ito
authors.forename: K
authors.initials: K
authors.lastname: Kumakawa
mesh_terms: D000283:Administration, Intravesical; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011182:Postoperative Care; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; C027260:pirarubicin